/ALCJ.PA
ALCJ.PA Stock - Crossject S.A.
Healthcare|Medical - Instruments & SuppliesPAR
$2.13+4.15%
+$0.09 (+4.15%) • Dec 23
70
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.64
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.97
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $2.35
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ALCJ.PA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.11 – $2.16
TARGET (TP)$2.46
STOP LOSS$1.96
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.57
52W High$2.69
52W Low$0.72
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $4.12M | $145,000 | $954,000 | $912,000 | $4.84M |
| Gross Profit | $-21,893,000 | $-6,135,000 | $-13,894,000 | $-11,063,000 | $894,735 |
| Gross Margin | -532.0% | -4231.0% | -1456.4% | -1213.0% | 18.5% |
| Operating Income | $-15,238,000 | $-11,800,000 | $-13,228,000 | $-11,823,000 | $-10,892,700 |
| Net Income | $-12,795,000 | $-8,638,000 | $-11,157,000 | $-10,806,000 | $-9,844,051 |
| Net Margin | -310.9% | -5957.2% | -1169.5% | -1184.9% | -203.2% |
| EPS | $-0.28 | $-0.23 | $-0.31 | $-0.42 | $-0.41 |
Company Overview
Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ALCJ.PABeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.16
Q3 2024
EPS Surprise History
Q1 21
No data
Q3 21
No data
Q2 22
No data
Q4 22
No data
Q1 23
No data
Q4 23
No data
Q2 24
No data
Q3 24
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 25, 2026 | — | — | — | — |
Q3 2024 | Sep 23, 2024 | — | $-0.16 | — | — |
Q2 2024 | Apr 2, 2024 | — | $-0.11 | — | — |
Q4 2023 | Nov 1, 2023 | — | $-0.12 | — | — |
Q1 2023 | Mar 21, 2023 | — | $-0.14 | — | — |
Q4 2022 | Dec 26, 2022 | — | $-0.17 | — | — |
Q2 2022 | May 5, 2022 | — | $-0.20 | — | — |
Q3 2021 | Sep 22, 2021 | — | $-0.21 | — | — |
Q1 2021 | Mar 30, 2021 | — | $-0.19 | — | — |
Q4 2020 | Dec 10, 2020 | — | $-0.22 | — | — |
Q2 2020 | May 19, 2020 | — | $-0.11 | — | — |
Q3 2019 | Sep 10, 2019 | — | $-0.27 | — | — |
Q1 2019 | Mar 15, 2019 | — | $-0.42 | — | — |
Q3 2018 | Sep 26, 2018 | — | $-0.35 | — | — |
Q1 2018 | Mar 20, 2018 | — | $-0.47 | — | — |
Q3 2017 | Sep 21, 2017 | — | $-0.38 | — | — |
Q1 2017 | Mar 9, 2017 | — | $-0.50 | — | — |
Q3 2016 | Sep 20, 2016 | — | $-0.41 | — | — |
Q1 2016 | Feb 16, 2016 | — | $-0.32 | — | — |
Q3 2015 | Sep 15, 2015 | — | $-0.53 | — | — |
Latest News
Loading news...
Frequently Asked Questions about ALCJ.PA
What is ALCJ.PA's current stock price?
Crossject S.A. (ALCJ.PA) is currently trading at $2.13 per share. The stock has moved +4.15% today.
What is the analyst price target for ALCJ.PA?
No analyst price targets are currently available for this stock.
What sector is Crossject S.A. in?
Crossject S.A. operates in the Healthcare sector, specifically within the Medical - Instruments & Supplies industry. The company is traded on the PAR exchange.
What is ALCJ.PA's market cap?
Crossject S.A. has a market capitalization of $0.11 billion, making it a small-cap company.
Does ALCJ.PA pay dividends?
No, Crossject S.A. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABNX.PA
ABIONYX Pharma S.A.
$3.55
Mkt Cap: $0.1B
AB.PA
AB Science S.A.
$1.38
Mkt Cap: $0.1B
ADOC.PA
Adocia S.A.
$6.49
Mkt Cap: $0.1B
AFME.PA
Affluent Medical S.A.
$2.10
Mkt Cap: $0.1B
ALECR.PA
Eurofins-Cerep S.A.
$17800.00
Mkt Cap: $0.1B
ALKLH.PA
Klea Holding
$0.23
Mkt Cap: $0.1B
ALMDT.PA
Median Technologies S.A.
$4.42
Mkt Cap: $0.2B
ALSEN.PA
Sensorion S.A.
$0.33
Mkt Cap: $0.1B
IPH.PA
Innate Pharma S.A.
$1.56
Mkt Cap: $0.1B
OSE.PA
OSE Immunotherapeutics S.A.
$4.93
Mkt Cap: $0.1B
Explore stocks similar to ALCJ.PA for comparison